Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ondine Biomedical, Inc. ( (GB:OBI) ) has issued an announcement.
Ondine Biomedical Inc. has announced its innovative light-activated antimicrobial treatment for nasal decolonization, which could become the first FDA-approved method for preventing surgical site infections (SSIs) in the US. This new treatment, currently in phase 3 trials, offers a significant improvement over the current use of mupirocin by eliminating the need for a demanding regimen and addressing antimicrobial resistance concerns. With SSIs accounting for a substantial portion of hospital-associated infections and their high costs, the adoption of Ondine’s treatment could lead to cost savings, reduced surgical waitlists, and improved patient outcomes. The company has successfully treated over 200,000 patients in Canada and the UK and has partnered with Mölnlycke Health Care to distribute its technology across the UK, EU, and Middle East, highlighting its growth and potential impact on the medical field.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photo disinfection. The company has a range of investigational products based on its proprietary technology, including a nasal photodisinfection system called Steriwave, which is approved in Canada and several other countries. Ondine is in the process of seeking regulatory approval in the US, where it has received a Qualified Infectious Disease Product designation and Fast Track status by the FDA. The company is also developing therapies for chronic sinusitis, ventilator-associated pneumonia, burns, and other medical indications.
YTD Price Performance: 37.14%
Average Trading Volume: 482,511
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £48.48M
For an in-depth examination of OBI stock, go to TipRanks’ Stock Analysis page.
